Hairy cell leukemia is a rare, slow-growing cancer of B lymphocytes, a type of white blood cell, named for the fine, hair-like projections visible on the surface of the abnormal cells under a microscope. It accounts for roughly 2 percent of all leukemias and tends to affect middle-aged to older men far more than women. Despite its rarity, hairy cell leukemia has an unusually good prognosis compared to other blood cancers: modern treatments can send it into long-lasting remission, and many patients live a normal lifespan.
Who Gets It
Hairy cell leukemia is uncommon by any measure. The incidence rate in white men in the United States is about 0.62 per 100,000 person-years, dropping to roughly 0.21 in Black men and 0.20 in Asian men. It is even rarer in women. In France, where large registries track the disease, the median age at diagnosis is 63 in men and 59 in women, with a male-to-female ratio of about 5 to 1.1Medical Research Archives. Epidemiology of Hairy Cell Leukemia (HCL) and HCL-Like Disorders That sex imbalance is one of the steepest in all of oncology, and researchers still do not fully understand why men are so disproportionately affected.
Risk Factors and Possible Causes
The underlying cause of hairy cell leukemia remains uncertain, but a few environmental exposures keep turning up in research. Farming and agricultural work are the most consistent risk factor. A pooled analysis from the InterLymph consortium found that people who had ever worked as mixed animal and crop farmers had more than double the odds of developing the disease compared to people who never farmed, and the risk rose with longer duration of farming.2JNCI Monographs. Medical History, Lifestyle, and Occupational Risk Factors for Hairy Cell Leukemia: The InterLymph Non-Hodgkin Lymphoma Subtypes Project A Scandinavian case-control study found elevated risk with exposure to herbicides, fungicides, insecticides, organic solvents, and exhaust fumes, though the authors flagged that recall bias could have inflated some of the pesticide associations.3PubMed Central. Occupational exposures, animal exposure and smoking as risk factors for hairy cell leukaemia evaluated in a case-control study Contact with farm animals, particularly cattle, was also linked to higher risk in that study.
None of these exposures have been established as definitive causes, partly because hairy cell leukemia is so rare that large prospective studies are difficult to run. The farming connection, however, is among the most replicated findings in the field and remains a focus of ongoing investigation.
The BRAF Mutation at the Heart of the Disease
A landmark discovery in 2011 changed how researchers think about hairy cell leukemia. A team found that virtually all cases of classic hairy cell leukemia carry a single specific mutation in the BRAF gene, called V600E. This mutation locks a signaling pathway into a permanently “on” position, telling the leukemia cells to keep surviving and dividing regardless of normal growth signals.4PubMed Central. BRAF Mutations in Hairy-Cell Leukemia The same BRAF V600E mutation shows up in melanoma and certain thyroid cancers, but among B-cell cancers, hairy cell leukemia is the only one driven by this particular activating mutation in a kinase-encoding gene.5Blood. BRAF V600E mutation in hairy cell leukemia: from bench to bedside
This finding was not just academic. It immediately opened the door to targeted therapy with drugs already developed for BRAF-mutated melanoma, and it gave doctors a reliable molecular marker to confirm the diagnosis. When researchers incubated hairy cells from patients with a BRAF inhibitor in the laboratory, the downstream signaling proteins switched off markedly.6PubMed Central. BRAF Mutations in Hairy-Cell Leukemia That observation translated directly into clinical trials.
What Symptoms Look Like
Most people with hairy cell leukemia are diagnosed after routine blood work reveals abnormalities, often before they feel particularly unwell. The leukemia cells accumulate in the bone marrow and spleen, crowding out normal blood-cell production. That leads to a recognizable triad of problems: low red blood cells (causing fatigue and pallor), low platelets (causing easy bruising and bleeding), and low healthy white blood cells (causing frequent or unusual infections). An enlarged spleen is found in the majority of patients at diagnosis, though not in every case.7Blood Research. Hairy cell leukemia: a case report of atypical presentation without splenomegaly
The infection risk deserves special attention. Hairy cell leukemia appears to cause a specific defect in how the immune system’s monocytes function. Patients are susceptible not just to ordinary bacterial infections but to unusual organisms, including atypical mycobacteria, a group of pathogens that healthy immune systems generally handle without trouble.8PubMed. Disseminated atypical mycobacterial infection in hairy cell leukemia This immune vulnerability is part of why treatment, even in patients who feel relatively well, is often recommended sooner rather than later when blood counts are falling.
How the Diagnosis Is Made
Hairy cell leukemia has a distinctive appearance under the microscope: medium-sized cells with pale blue cytoplasm and those namesake hair-like projections along their edges. But morphology alone is not enough, because several other B-cell cancers can look confusingly similar.9PubMed Central. Hairy cell leukemia diagnostic criteria and differential diagnosis The workup almost always includes a bone marrow biopsy. Trying to aspirate bone marrow with a needle frequently yields a “dry tap” because the leukemia cells cause fibrosis in the marrow space.10Blood Research. Hairy cell leukemia: a case report of atypical presentation without splenomegaly
Flow cytometry, a technique that identifies cells by the proteins on their surface, is central to confirming the diagnosis. Classic hairy cell leukemia cells characteristically express a combination of markers including CD25, CD103, CD123, and CD11c. Cells that also stain positive for annexin A1 strongly support a classic hairy cell leukemia diagnosis over look-alike conditions.11American Journal of Clinical Pathology. Immunophenotypic Analysis of CD103+ B-Lymphoproliferative Disorders: Hairy Cell Leukemia and Its Mimics More recently, adding CD26 to the diagnostic panel has been shown to push specificity to 100 percent, meaning that when CD26 is included, hairy cell leukemia can be reliably distinguished from its look-alikes.12PubMed Central. Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders CD200, expressed at high levels in classic hairy cell leukemia compared to other B-cell cancers, offers another useful distinguishing marker.13American Journal of Clinical Pathology. CD200 Flow Cytometric Assessment and Semiquantitative Immunohistochemical Staining Distinguishes Hairy Cell Leukemia From Hairy Cell Leukemia-Variant and Other B-Cell Lymphoproliferative Disorders
Testing for the BRAF V600E mutation now rounds out the diagnostic picture. A positive BRAF test essentially confirms classic hairy cell leukemia, while a negative result in a case that otherwise looks like hairy cell leukemia should prompt consideration of a variant form or a different diagnosis entirely.
First-Line Treatment With Purine Analogs
Before the 1980s, the only real option was removing the spleen. Splenectomy improved blood counts in most patients, but responses were temporary, lasting a median of about 19 months before the disease worsened again. Interferon-alpha, introduced in the early 1980s, produced similar overall response rates but slightly longer benefit. The real transformation came with two drugs called purine nucleoside analogs: cladribine and pentostatin.14PubMed. Fifty years of hairy cell leukemia treatments
Cladribine, typically given as a single seven-day intravenous infusion, achieves complete response rates approaching 95 percent.15PubMed Central. My treatment approach to hairy cell leukemia Pentostatin, administered on a different schedule, produces comparable results. Long-term follow-up data show an overall complete response rate of about 81 percent with a median disease-free survival of 16 years.16PubMed. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia For a cancer, those numbers are remarkable. A single course of treatment can keep the disease in check for well over a decade in most patients.
The downside is that purine analogs are powerfully immunosuppressive. They wipe out T cells along with the leukemia, leaving patients vulnerable to infections for weeks to months after treatment. And while most patients achieve deep remissions, hairy cell leukemia is not considered cured by chemotherapy alone: with long enough follow-up, a significant minority of patients do eventually relapse and need further treatment.
What Happens When the Disease Comes Back
For patients who relapse after purine analogs, several newer options are available. The discovery of the BRAF V600E mutation made it logical to try vemurafenib, a BRAF inhibitor already approved for melanoma. In two phase 2 trials, a short oral course of vemurafenib produced overall response rates of 96 to 100 percent in patients with relapsed or refractory hairy cell leukemia, with complete response rates in the range of 35 to 42 percent.17PubMed Central. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia Responses came quickly, often within two to three months.
Another option for heavily pretreated patients is moxetumomab pasudotox, an immunotoxin that targets CD22, a protein found at high levels on hairy cell leukemia cells. The FDA approved it in 2018 for patients who had received at least two prior treatments including a purine analog.18PubMed. Moxetumomab pasudotox for the treatment of hairy cell leukemia In its pivotal trial of 80 patients, the drug produced complete responses in about 41 percent and achieved hematologic remission in 80 percent. Among those who achieved complete response, 85 percent also cleared detectable residual disease.19PubMed Central. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Ibrutinib, a pill originally developed for other B-cell cancers, has also been studied in hairy cell leukemia. While the initial primary endpoint of the phase 2 trial was not met, the drug did produce objective responses in about half of heavily pretreated patients, and the estimated 36-month progression-free survival was 73 percent. Side effects including diarrhea, fatigue, and low blood counts were common.20PubMed Central. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia Ibrutinib is not a frontline choice, but it gives doctors another tool for patients who have run through other options.
The Variant That Behaves Differently
Not everything that looks hairy under the microscope is classic hairy cell leukemia, and getting the distinction right matters. The most important look-alike used to be called hairy cell leukemia variant (HCL-v), but the latest WHO classification has retired that name. The current system groups splenic B-cell cancers into four entities: classic hairy cell leukemia, splenic marginal zone lymphoma, splenic diffuse red pulp lymphoma, and a newly defined category called splenic lymphoma with prominent nucleolus (which absorbs the old HCL-v category).21PubMed Central. Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment
These distinctions matter because the variant forms generally lack the BRAF V600E mutation and do not respond well to purine analogs alone. In variant cases, researchers have instead found frequent activating mutations in the MAP2K1 gene, present in about 48 percent of cases tested. These mutations were mutually exclusive with BRAF V600E.22PubMed Central. High prevalence of MAP2K1 mutations in variant and IGHV4-34 expressing hairy-cell leukemia The discovery of MAP2K1 mutations has opened interest in drugs targeting MEK, though treatment for variant disease remains less standardized than for the classic form. Cases that lack CD25 and annexin A1 on flow cytometry behave clinically differently from classic hairy cell leukemia and should be separated from it at diagnosis.23American Journal of Clinical Pathology. Immunophenotypic Analysis of CD103+ B-Lymphoproliferative Disorders: Hairy Cell Leukemia and Its Mimics
Tracking Residual Disease After Treatment
Even when blood counts return to normal and the bone marrow looks clean on standard staining, small numbers of leukemia cells can persist. Detecting these hidden cells, known as measurable residual disease, has become an important part of managing hairy cell leukemia. Studies have shown that patients who test negative for residual disease after treatment are much less likely to relapse than those who still have detectable cells.24PubMed Central. Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
One early study using sensitive staining found that about 13 percent of patients who appeared to be in complete remission after cladribine still harbored residual disease at three months. Half of those patients went on to relapse, compared to only about 4 percent of patients without detectable residual disease.25Blood. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine A separate study found that estimated four-year relapse-free survival was about 55 percent in patients with residual disease versus about 88 percent in those without it.26Clinical Cancer Research. Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2-Chlorodeoxyadenosine or 2′-Deoxycoformycin and Prediction of Early Relapse Whether aggressively treating residual disease improves long-term outcomes is still being studied, but these findings have made residual-disease testing a routine part of post-treatment monitoring at many centers.
Long-Term Outlook and Life Expectancy
For a leukemia diagnosis, the long-term picture in hairy cell leukemia is reassuringly good. A 35-year single-center study found that patients treated with purine analogs had overall survival equivalent to age- and sex-matched members of the general population, with a standardized mortality ratio of 0.8, meaning patients were actually dying at a slightly lower rate than the comparison group (though the confidence interval would include 1.0).27PubMed Central. Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population That is about as close to “cured in practice” as a chronic blood cancer gets.
There is one important caveat. A large population-based study of over 3,100 patients found that the risk of developing a second, different cancer after hairy cell leukemia is modestly elevated compared to the general population. The biggest increases were in non-Hodgkin lymphoma, Hodgkin lymphoma, and thyroid cancer. Interestingly, lung cancer risk was actually lower than expected, and deaths from heart disease and stroke were also below the population average.28JNCI: Journal of the National Cancer Institute. Second Cancer Incidence and Cause-Specific Mortality Among 3104 Patients With Hairy Cell Leukemia: A Population-Based Study The cumulative probability of any second cancer was estimated at about 32 percent at 25 years after diagnosis, which is worth knowing but needs context: these are mostly older adults being followed for decades, an age range where cancer of any kind becomes increasingly common. The absolute excess, roughly 34 additional cancers per 10,000 patients per year, is modest.
Living With the Diagnosis Day to Day
Because hairy cell leukemia is indolent and treatment often produces very long remissions, many patients spend the majority of their time in a “watch and wait” posture. After an initial course of cladribine or pentostatin, follow-up typically involves periodic blood counts and occasional bone marrow biopsies. Some patients never need a second round of treatment.
Infections remain the chief practical concern, both during treatment and sometimes even in remission, because the underlying immune defect does not always fully resolve. Patients are generally advised to stay current on vaccinations (to the extent allowed by their immune status), report fevers promptly, and be aware that unusual infections, including those caused by organisms that rarely bother healthy people, can occasionally occur. The monocyte dysfunction linked to hairy cell leukemia is distinct from the immunosuppression caused by treatment; the two can compound each other during and shortly after therapy.
For people newly diagnosed, it helps to know that the treatment landscape has expanded dramatically over the past four decades. Where splenectomy was once the only option, patients now have purine analogs as a highly effective first line, BRAF inhibitors for relapse, an FDA-approved immunotoxin for multiply relapsed disease, and experimental agents like BTK inhibitors in trials. The pace of discovery in this small corner of hematology has been disproportionately fast, in part because the BRAF V600E mutation gave researchers a clear molecular target that connected hairy cell leukemia to a much larger world of targeted-therapy development in other cancers.